<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="editorial" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28589177</article-id>
<article-id pub-id-type="pmc">5446781</article-id>
<article-id pub-id-type="publisher-id">NG2017005355</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000159</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>14</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>ARHGEF9</italic> mutations cause a specific recognizable X-linked intellectual disability syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Striano</surname>
<given-names>Pasquale</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Italian Agency of the Drug (AIFA)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Memebr of the Editorial Board of Epilepsia</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zara</surname>
<given-names>Federico</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>Italian Ministry of Health, RF-2010-2314356), Principal investigator, 2013-2016.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Laboratory of Neurogenetics (P.S.), Istituto “Giannina Gaslini,” Genova, Italy; and Pediatric Neurology and Muscular Diseases Unit (F.Z.), Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, “G. Gaslini” Institute, Italy.</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence to Dr. Striano: <email>strianop@gmail.com</email></corresp>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the editorial. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000159">Neurology.org/ng</ext-link> for full disclosure forms. The Article Processing Charge for this editorial was waived at the discretion of the Editor.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>26</day>
<month>5</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>3</volume>
<issue>3</issue>
<elocation-id>e159</elocation-id>
<permissions>
<copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2017005355.pdf" xlink:title="pdf"></self-uri>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Mutations in more than 100 genes have been reported to cause X-linked intellectual disability (XLID), mainly in males. By contrast, the identified X-linked genes in which de novo mutations specifically cause ID in females are still limited so far.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Next-generation sequencing has nowadays enabled the screening for a causative mutation in XLID using targeted panel, X-exome, and whole-exome sequencing methods.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> Mutations in the X-linked cell division cycle 42 guanine nucleotide exchange factor (GEF)-9 gene (<italic>ARHGEF9</italic>) have been recently associated with a wide phenotypic spectrum, including ID, behavior disorders, autism spectrum disorder, hyperekplexia, and infantile epileptic encephalopathy.<sup><xref ref-type="bibr" rid="R3">3</xref><xref ref-type="bibr" rid="R4">–</xref><xref ref-type="bibr" rid="R5">5</xref></sup> A number of patients with <italic>ARHGEF9</italic> mutations, encompassing missense and nonsense mutations, deletions, and complex rearrangements, have been reported. However, so far, the clinical features of <italic>ARHGEF9</italic> disease are nonspecific, with extreme phenotypic and genetic heterogeneity.</p>
<p>In this issue of <italic>Neurology</italic>® <italic>Genetics</italic>, Alber et al.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> report 18 patients (including 5 females) identified through clinical practice (8 previously unpublished) and from a review of the literature. Detailed medical history and examination findings were obtained for each patient via a standardized questionnaire. Patients' age widely ranged from 4 to 57 years, and age at onset of the symptoms varied from day 1 to age 7 years, with a mean age of 15 months. Presenting symptoms included seizures (5 patients), developmental delay in combination with seizures (4 subjects), and developmental delay/ID alone (6 patients). Most patients (13 subjects) showed delayed early developmental milestones, and all individuals had ID ranging from mild-moderate to severe degree, with associated autistic features or hyperactivity/aggressive behavior in some cases. Thirteen patients had epilepsy with onset at a mean age of 20 months (range: 1 week–7 years). Seizure types were variable, including tonic-clonic seizures in 9 subjects, focal in 9, tonic in 2, and myoclonic in 1 individual. EEG recordings revealed generalized, focal, or even multifocal epileptic abnormalities. All patients with epilepsy were treated with antiseizure drugs, usually a polytherapy, and seizures were drug resistant in 4 cases. Minor abnormalities on neuroimaging were observed in 8 subjects and included nonspecific T2 hyperintensities/enlarged perivascular spaces in 3 subjects and hippocampal sclerosis, hypoplastic frontal lobe, brain atrophy, polymicrogyria, and delayed myelination in 1 each. Eight subjects had de novo hemizygous single nucleotide mutations, 3 had maternally inherited mutations, and 7 carried chromosomal disruptions. All female patients had strongly skewed X-inactivation. However, the most important merit of this article is to provide quite accurate genotype-phenotype correlations. Indeed, ID was moderate in individuals carrying with less severe mutations. Moreover, male patients were most severely affected with the overall neurologic syndrome (i.e., most severe ID and seizures) and showed distinctive and consistent facial features, including enlarged, fleshy ear lobes, and sunken appearance of the middle face (i.e., midface hypoplasia) in combination with prognathism. Finally, all the 3 male patients harboring mutations in exon 9 that do affect a specific pleckstrin homology (PH) domain of the protein did not develop epilepsy.</p>
<p><italic>ARHGEF9</italic> encodes collybistin, a protein which is highly expressed in multiple regions of the brain during development and structured by an N-terminal SRC homology 3 (SH3) domain followed by tandem DBL homology (DH), PH domains, and a C-terminal proline-rich sequence.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> This protein structure identifies <italic>ARHGEF9</italic> as a member of the Rho GTPase activator family, responsible for the activation of Rho-family GTPases and involved in a number of cell signaling transduction pathways.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> In addition, collybistin is essential for the clustering of the scaffolding protein gephyrin and of GABAA receptors at the postsynaptic membrane, 2 proteins associated with ID and epilepsy.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> The reduction of inhibitory receptor clusters in the brain has been proposed as a plausible underlying pathophysiologic mechanism. In fact, collybistin-deficient male mice show reduced exploratory behavior, impaired spatial learning, increased anxiety scores, and reduction of gephyrin-dependent GABA receptor clusters in amygdala and hippocampus.<sup><xref ref-type="bibr" rid="R7">7</xref></sup></p>
<p>The reasons behind the clinical variability of <italic>ARHGEF9</italic> mutations remain unknown and could be to be linked to several factors. First, the clinical features observed in mutated females may depend on the degree of X-inactivation skewing. Thus, while males have more pronounced ID and dysmorphic features, females may show variable symptoms with a phenotype similar to that of males when displaying the 100% X-inactivation.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> However, X-inactivation and expression in blood might not necessarily reflect what is occurring in the brain, and other factors may modify expression, such as variants in regulatory sequences of <italic>ARHGEF9</italic> and related genes. Second, certain <italic>ARHGEF9</italic> mutations (e.g., C-terminal truncations) clearly cause dominant-negative effects on gephyrin and GABAA receptor clustering in neuronal systems.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> Moreover, functional studies of <italic>ARHGEF9</italic> missense mutations affecting the PH domain structure that binds phosphatidylinositol-3-phosphate show consequent loss in the ability of collybistin to mediate gephyrin clustering.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> Nevertheless, given the variability in clinical phenotypes associated with <italic>ARHGEF9</italic> mutations, it is evident that clinical observation, flanked by molecular genetics, is the best approach for a correct approach to patients with ID and other neuropsychiatric features. In fact, patients with ID often undergo a diagnostic odyssey before receiving the correct diagnosis, mainly because of clinical heterogeneity, unusual presentations, and lack of specific genotype-phenotype correlations. On the other hand, the identification of the disease-related mutation is of paramount importance to patients and their families, as awareness of the causing condition relieves uncertainty, improves communication with professionals, and provides prognostic information and enhances social support. Alber et al.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> provide an excellent clinical genetic summary of the <italic>ARHGEF9</italic> mutations, providing great aid in the clinical dissection of <italic>ARHGEF9</italic> variants. Further observations and longitudinal follow-up studies are warranted in the future to clarify the full spectrum of <italic>ARHGEF9</italic> disease and to shed light on the accumulating evidence implicating neuronal synaptic gene products as key molecular factors underlying the etiologies of a diverse range of neurodevelopmental conditions.</p>
</body>
<back>
<fn-group>
<fn fn-type="other">
<p>
<ext-link ext-link-type="uri" xlink:href="http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000148">See article</ext-link>
</p>
</fn>
</fn-group>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">No targeted funding reported.</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">P. Striano received honoraria from FB Health, Kolfarma s.r.l., UCB pharma, and Eisai Inc. and research support from the Italian Ministry of Health and the Telethon Foundation. F. Zara received research support from the Italian Ministry of Health, the European Community Sixth, the Italian Ministry of Health, the Telethon Foundation, and the Italian League Against Epilepsy. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000159">Neurology.org/ng</ext-link> for full disclosure forms.</p>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarpey</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pleasance</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation</article-title>. <source/>Nat Genet
<year>2009</year>;<volume>41</volume>:<fpage>535</fpage>–<lpage>543</lpage>.<pub-id pub-id-type="pmid">19377476</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Ligt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Willemsen</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>van Bon</surname><given-names>BW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>. <source/>N Engl J Med
<year>2012</year>;<volume>367</volume>:<fpage>1921</fpage>–<lpage>1929</lpage>.<pub-id pub-id-type="pmid">23033978</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lesca</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Till</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Labalme</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo Xq11.11 microdeletion including ARHGEF9 in a boy with mental retardation, epilepsy, macrosomia, and dysmorphic features</article-title>. <source/>Am J Med Genet A
<year>2011</year>;<volume>155A</volume>:<fpage>1706</fpage>–<lpage>1711</lpage>.<pub-id pub-id-type="pmid">21626670</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalscheuer</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Musante</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation</article-title>. <source/>Hum Mutat
<year>2009</year>;<volume>30</volume>:<fpage>61</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">18615734</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>P</given-names></name>, <name name-style="western"><surname>May</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>James</surname><given-names>VM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Missense mutation R338W in ARHGEF9 in a family with X-linked intellectual disability with variable macrocephaly and macro-orchidism</article-title>. <source/>Front Mol Neurosci
<year>2016</year>;<volume>8</volume>:<fpage>83</fpage>.<pub-id pub-id-type="pmid">26834553</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alber</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kalscheuer</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Marco</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title><italic>ARHGEF9</italic> disease: phenotype clarification and genotype-phenotype correlation</article-title>. <source/>Neurol Genet
<year>2017</year>;<volume>3</volume>:<fpage>e148</fpage>
<ext-link ext-link-type="uri" xlink:href="http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000148">doi: 10.1212/NXG.0000000000000148</ext-link>.</mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jaiswal</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Collybistin activation by GTP-TC10 enhances postsynaptic gephyrin clustering and hippocampal GABAergic neurotransmission</article-title>. <source/>Proc Natl Acad Sci USA
<year>2013</year>;<volume>110</volume>:<fpage>20795</fpage>–<lpage>20800</lpage>.<pub-id pub-id-type="pmid">24297911</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saiepour</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fuchs</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Patrizi</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Complex role of collybistin and gephyrin in GABAA receptor clustering</article-title>. <source/>J Biol Chem
<year>2010</year>;<volume>285</volume>:<fpage>29623</fpage>–<lpage>29631</lpage>.<pub-id pub-id-type="pmid">20622020</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimojima</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sugawara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shichiji</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy</article-title>. <source/>J Hum Genet
<year>2011</year>;<volume>56</volume>:<fpage>561</fpage>–<lpage>565</lpage>.<pub-id pub-id-type="pmid">21633362</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulos</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schemm</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Grubmüller</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Brose</surname><given-names>N</given-names></name></person-group>
<article-title>Lipid binding defects and perturbed synaptogenic activity of a Collybistin R290H mutant that causes epilepsy and intellectual disability</article-title>. <source/>J Biol Chem
<year>2015</year>;<volume>290</volume>:<fpage>8256</fpage>–<lpage>8270</lpage>.<pub-id pub-id-type="pmid">25678704</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>